14 February 2020

NBE-Therapeutics AG closed a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders. The funds will enable NBE to advance development of the lead asset NBE-002 through early clinical trials and to further strengthen the development team, management and board of the company. NBE-Therapeutics’ best in class iADCTM platform creates highly potent and safe immune-stimulatory ADCs with an anthracycline payload, inducing a long-lasting immunological anti-tumor effect.

VISCHER has been assisting the investors in the financing round, the team was led by Matthias Staehelin with Vincent Reardon and Bettina Achermann (all Corporate).

Press release

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital

You are currently offline. Some pages or content may fail to load.